The original headline mistakenly said Biometra will resume selling its thermocycler business. In fact it will resume selling the instruments.
 
NEW YORK (GenomeWeb News) — Whatman today said it has settled a lawsuit involving its Biometra subsidiary that will enable it to resume selling thermocyclers.
 
The company also said it is firing CEO Bill Emhiser immediately for “disappointing trading” last year. He will be replaced by former Innovata CEO Kieran Murphy.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Gene therapies could qualify for a faster US Food and Drug Administration approval process, according to Stat News.

Science speaks with the University of Michigan's Jedidiah Carlson, who has tracked population genetic discussions at white nationalist sites.

NPR reports that the US House of Representatives has passed a bill to enable terminally ill patients access to experimental drugs.

In Genome Research this week: inversion variants mapped in human, non-human primate genomes; transcriptome profiling of maize, sorghum; and more.